Description
Background:
Nivolumab is a genetically engineered anti-PD-1 mAb that binds to PD-1 with high affinity and blocks its interactions with both PD-L1 and PD-L2, thereby stimulates memory response to tumor antigen-specific T cell proliferation. It is a prescription medicine used in combination with ipilimumab as a first treatment for adults with a non-small cell lung cancer that are positive for PD-L1, but do not have an abnormal EGFR or ALK gene.
Intended Use:
For Estimation of Nivolumab (OPDIVO) in human serum and plasma. Please note the kit has not been optimized to be used for any other animal species. Should you require a specific sera tested, please connect with us at sales@krishgen.com for optimization.
Principle:
The method employs the quantitative sandwich enzyme immunoassay technique. Antibodies to Nivolumab are pre-coated onto microwells. Samples and standards are pipetted into microwells and human Nivolumab present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated anti-nivolumab antibody is pipetted and incubated. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Nivolumab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!